Leucine-rich repeat kinase 2 (LRRK2) phosphorylates a subset of Rab GTPases that regulate receptor trafficking; activating mutations in LRRK2 are linked to Parkinson’s disease. Rab phosphorylation is a transient event that can be reversed by phosphatases, including PPM1H, that acts on phosphoRab8A and phosphoRab10. Here we report a phosphatome-wide siRNA screen that identified PPM1M as a phosphoRab12-preferring phosphatase that also acts on phosphoRab8A and phosphoRab10. Upon knockout from cells or mice, PPM1M displays selectivity for phosphoRab12. As shown previously for mice harboring LRRK2 pathway mutations, knockout of Ppm1m leads to primary cilia loss in striatal cholinergic interneurons. We have also identified a rare PPM1M mutation in patients with Parkinson’s disease that is catalytically inactive when tested in vitro and in cells. These findings identify PPM1M as a key player in the LRRK2 signaling pathway and provide a new therapeutic target for the possible benefit of patients with Parkinson’s disease. Teaser: Parkinson’s linked Rab phosphorylation is reversed by PPM1M; the inactive D440N variant is implicated in rare patient cases.
Pathogenic variants in leucine-rich repeat kinase 2 ( LRRK2 ) 1 are among the most frequent monogenic causes of Parkinson’s disease (PD) 2 and act through a gain-of-function mechanism of increased kinase activity. LRRK2 -targeted therapies are in clinical development, but interpretation of the rapidly expanding catalogue of rare LRRK2 variants remains a barrier to translation. Here, we present functionally annotated data on >350 LRRK2 coding variants using a standardized cellular assay with Rab10 phosphorylation as a readout of kinase activity and integrated these data with curated genetic and clinical annotations from the Movement Disorders Society Genetic Mutation Database (MDSGene). Variants differed in activation magnitude, ranging from modest increases (e.g., p.G2019S) to strongly activating substitutions such as p.Y1699C or p.L1795F. Activating variants occurred across the full length of LRRK2, although the largest effects clustered within the ROC–COR regulatory hub, where structural analysis identified subdomains forming an allosteric scaffold controlling kinase output. All known/established pathogenic variants showed increased activity, whereas benign and likely benign variants remained within the wild-type range. Functional effect sizes correlated with pathway activation in patient-derived immune cells, altogether providing a framework for ACMG-based variant interpretation in which kinase activation can support PS3 functional evidence for reclassification of variants.
Background: Gain-of-kinase-function variants in LRRK2 are a leading cause for Parkinson’s disease (PD). Objectives: We tested the functional impact of a novel LRRK2 variant p.V1447L identified in a young onset PD patient in vivo in peripheral blood as well as in a robust cellular assay in addition to other variants in close proximity to V1447. Methods: We measured LRRK2-dependent Rab10 phosphorylation in neutrophils and monocytes of a LRRK2 p.V1447L carrier with PD. We deployed structural modelling and evaluated the impact of additional LRRK2 variants at and around LRRK2 V1447. Results: LRRK2 p.V1447L strongly activates LRRK2 kinase activity. We identified additional variants in the LRRK2 ROC:COR B interface with critical impact on kinase activity and show that different substitutions at the same residue can have opposing effects. Conclusions: We recommend reclassifying LRRK2 p.V1447L from VUS to likely pathogenic. Our study expands the range of putative Loss-of-kinase function variants to LRRK2 missense variants.
Pathogenic LRRK2 variants cause Parkinson’s disease (PD) through increased kinase activity, with VPS35 p.D620N and other emerging genetic factors also increasing LRRK2 signalling. Findings in idiopathic PD also suggest broader LRRK2 pathway involvement. As LRRK2-targeted therapies advance, identifying patients with elevated LRRK2 kinase activity beyond known mutations is essential. Here, we quantified LRRK2-dependent Rab10 phosphorylation at threonine 73 in blood neutrophils from 181 genetically enriched PD patients and 71 controls. Whole-exome sequencing identified pathogenic and rare variants. VPS35 p.D620N carriers showed marked LRRK2 pathway activation, defining a biological reference threshold. Fourteen percent of PD patients without recognised pathogenic variants exhibited similar or greater pathway activation. In a subset of PD patients with increased LRRK2 pathway activity, genes harbouring rare variants were selected for exploratory functional assessment using siRNA knockdown in A549 cells. The screen identified several candidate genetic modifiers of LRRK2 signalling, including NECAP2. Overall, functional assessment of LRRK2 pathway activity identified a subset of PD patients with convergent pathway activation despite the absence of recognised pathogenic variants, supporting the integration of functional pathway phenotyping with genomic analysis for patient stratification.